New Leads. New Hope.

Acelot is a development stage biopharmaceutical company focused on therapies for Alzheimer’s Disease and central nervous system disorders. Our revolutionary JPS technology allows us to develop on-target therapies with a high degree of therapeutic predictability.

Abeta Oligomer Blockers

Recent work (Krafft et al., Cell 2013) has demonstrated that amyloid beta oligomers are the synaptotoxic entity at the earliest stages of Alzheimer’s Disease. Acelot has identified novel brain-penetrant small molecule antagonists of synaptotoxic amyloid oligomer action. Acelot has identified several families of potential oligomer antagonists via the JPS…

Read More

LXR-beta Selective Agonists

It is widely held that soluble Aβ oligomers are the most neurotoxic form of Aβ and that a compromised Aβ clearance rate in the brain may be one cause for late-onset Alzheimer’s disease. Key proteins that mediate Aβ clearance, are ApoE and the ABCA1 lipid transporter. Recent studies from…

Read More